These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 16290930

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
    Isaacs RC, Newton CL, Cutrona KJ, Mercer SP, Dorsey BD, McDonough CM, Cook JJ, Krueger JA, Lewis SD, Lucas BJ, Lyle EA, Lynch JJ, Miller-Stein C, Michener MT, Wallace AA, White RB, Wong BK.
    Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1532-5. PubMed ID: 21295466
    [Abstract] [Full Text] [Related]

  • 23. Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization.
    Endreas W, Brüßler J, Vornicescu D, Keusgen M, Bakowsky U, Steinmetzer T.
    ChemMedChem; 2016 Feb 04; 11(3):340-9. PubMed ID: 26662675
    [Abstract] [Full Text] [Related]

  • 24. Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human alpha-thrombin.
    Jiang H, Chen K, Tang Y, Chen J, Li Q, Wang Q, Ji R.
    J Med Chem; 1997 Sep 12; 40(19):3085-90. PubMed ID: 9301672
    [Abstract] [Full Text] [Related]

  • 25. Thrombin active site inhibitors.
    Das J, Kimball SD.
    Bioorg Med Chem; 1995 Aug 12; 3(8):999-1007. PubMed ID: 7582987
    [Abstract] [Full Text] [Related]

  • 26. Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.
    Obst U, Banner DW, Weber L, Diederich F.
    Chem Biol; 1997 Apr 12; 4(4):287-95. PubMed ID: 9195869
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.
    Thorstensson F, Kvarnström I, Musil D, Nilsson I, Samuelsson B.
    J Med Chem; 2003 Mar 27; 46(7):1165-79. PubMed ID: 12646027
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor.
    Kadono S, Sakamoto A, Kikuchi Y, Oh-eda M, Yabuta N, Koga T, Hattori K, Shiraishi T, Haramura M, Kodama H, Esaki T, Sato H, Watanabe Y, Itoh S, Ohta M, Kozono T.
    Biochem Biophys Res Commun; 2004 Nov 26; 324(4):1227-33. PubMed ID: 15504346
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
    Feng DM, Gardell SJ, Lewis SD, Bock MG, Chen Z, Freidinger RM, Naylor-Olsen AM, Ramjit HG, Woltmann R, Baskin EP, Lynch JJ, Lucas R, Shafer JA, Dancheck KB, Chen IW, Mao SS, Krueger JA, Hare TR, Mulichak AM, Vacca JP.
    J Med Chem; 1997 Nov 07; 40(23):3726-33. PubMed ID: 9371237
    [Abstract] [Full Text] [Related]

  • 34. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
    Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2865-70. PubMed ID: 18420408
    [Abstract] [Full Text] [Related]

  • 35. New cyanopeptide-derived low molecular weight thrombin inhibitors.
    Radau G, Gebel J, Rauh D.
    Arch Pharm (Weinheim); 2003 Aug 01; 336(8):372-80. PubMed ID: 14502757
    [Abstract] [Full Text] [Related]

  • 36. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI, Jin L, Rynkiewicz M, Gorga JC, Bibbins F, Meyers HV, Babine R, Strickler J.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):5022-7. PubMed ID: 16876411
    [Abstract] [Full Text] [Related]

  • 37. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
    Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, Weerasena V, Turner R, Koelsch G, Bilcer G, Tang J.
    J Med Chem; 2007 May 17; 50(10):2399-407. PubMed ID: 17432843
    [Abstract] [Full Text] [Related]

  • 38. Beyond heparinization: design of highly potent thrombin inhibitors suitable for surface coupling.
    Steinmetzer T, Baum B, Biela A, Klebe G, Nowak G, Bucha E.
    ChemMedChem; 2012 Nov 17; 7(11):1965-73. PubMed ID: 22907907
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. New tripeptidic thrombin inhibitors. Influence of P2 and P3 residues on activity and selectivity.
    De Nanteuil G, Gloanec P, Lila C, Portevin B, Boudon A, Rupin A, Verbeuren TJ.
    Bioorg Med Chem; 1995 Aug 17; 3(8):1019-24. PubMed ID: 7582976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.